Symetis and Boston Scientific reach USD 435 million purchase agreement
Symetis reaches key milestone: 1000 patients treated with ACURATE neo
Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system ACURATE neo™, and launches product with first commercial implantations
Symetis ACURATE TA™ confirms superior results in post-market registry.
Symetis announces successful, first time implantation of its ACURATE TA™ and ACURATE TF™ TAVI systems in Japan.
- 1 of 3
- next ›